We determined the role of these factors in the clinical phenotype and tumor microenvironment, we were surprised to find that, when these co-expression factors were highly expressed, the purity of the tumor was significantly reduced, the expression of TGFBR2 and the TGFBR3 were declined, the immune inflammatory response was weakened, the clinical stage of the patient was reduced, and the 5-year survival prognosis improved. This evidence concerns the gene TGFBR3 and neoplasm.